Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
biweekly
|
| gptkbp:analyzes |
filed
|
| gptkbp:barrelLength |
high
|
| gptkbp:clinicalTrials |
Phase 1
approximately 21 days multiple sites pending publication estimated 2 years NCT04212345 Phase 1 and beyond open-label, dose-escalation |
| gptkbp:collaborations |
clinical research organizations
|
| gptkbp:community_service |
overall response rate
|
| gptkbp:competitors |
oncology market
|
| gptkbp:currentStatus |
completed
|
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:dosageForm |
every 2 weeks
|
| gptkbp:environmentalConcerns |
associated biomarkers
|
| gptkbp:firstMatch |
2020
|
| gptkbp:hasPopulation |
diverse demographics
|
| gptkbp:healthcare |
ongoing
specific cancer types |
| gptkbp:historicalResearch |
expand indications
|
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb18049
|
| gptkbp:mandates |
cancer
|
| gptkbp:market |
high
|
| gptkbp:origin |
humanized
|
| gptkbp:partnerships |
pharmaceutical companies
|
| gptkbp:patentStatus |
patented
|
| gptkbp:productionCompany |
early clinical development
|
| gptkbp:regulatoryCompliance |
under investigation
|
| gptkbp:relatedEvent |
ongoing
|
| gptkbp:relatedTo |
immune system
|
| gptkbp:research |
grants and investments
|
| gptkbp:research_areas |
immuno-oncology
checkpoint inhibitors |
| gptkbp:researchAndDevelopment |
efficacy and safety data
|
| gptkbp:researchAreas |
cancer immunotherapy
|
| gptkbp:researchFocus |
oncology
|
| gptkbp:researchInterest |
academic institutions
improve patient outcomes published in peer-reviewed journals obtained |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
under evaluation
independent data monitoring committee |
| gptkbp:sideEffect |
immune-related adverse events
|
| gptkbp:sponsor |
gptkb:Xencor,_Inc.
|
| gptkbp:status |
investigational
|
| gptkbp:supplyChain |
managed_by_Xencor
|
| gptkbp:targets |
PD-1
patients with solid tumors |
| gptkbp:triggerType |
immune checkpoint inhibition
blocks PD-1 receptor |
| gptkbp:type |
IgG1
|